Non-small-cell lung cancer patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. The identification and implementation of predictive genetic markers of response-specific cytotoxic drugs is a priority of current research and future trials. In this study, we have used quantitative PCR to analyse expression of b-tubulin III, stathmin, RRM1, COX-2 and GSTP1 in mRNA isolated from paraffin-embedded tumor biopsies of 75 nonsmall-cell lung cancer patients treated as part of a large randomized trial. In total, 22 patients were treated with gemcitabine/cisplatin, 25 with vinorelbine/cisplatin and 28 with paclitaxel/carboplatin. There were no differences in clinical characteristics and transcript levels in the pretreatment biopsies according to treatment arm. Patients with low b-tubulin III levels had better response in the paclitaxel/carboplatin arm (P ¼ 0.05), and those with low RRM1 levels showed a tendency to better response in the gemcitabine/cisplatin arm. Time to progression was influenced by b-tubulin III (P ¼ 0.03) and stathmin (P ¼ 0.05) levels in the vinorelbine/cisplatin arm, and there was a tendency toward correlation between b-tubulin III levels and time to progression in the paclitaxel/carboplatin arm. RRM1 levels influenced time to progression (P ¼ 0.05) and even more so, survival (P ¼ 0.0028) in the gemcitabine/cisplatin arm. The predictive value of b-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival.
Non-small-cell lung cancer patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. The identification and implementation of predictive genetic markers of response-specific cytotoxic drugs is a priority of current research and future trials. In this study, we have used quantitative PCR to analyse expression of b-tubulin III, stathmin, RRM1, COX-2 and GSTP1 in mRNA isolated from paraffin-embedded tumor biopsies of 75 nonsmall-cell lung cancer patients treated as part of a large randomized trial. In total, 22 patients were treated with gemcitabine/cisplatin, 25 with vinorelbine/cisplatin and 28 with paclitaxel/carboplatin. There were no differences in clinical characteristics and transcript levels in the pretreatment biopsies according to treatment arm. Patients with low b-tubulin III levels had better response in the paclitaxel/carboplatin arm (P ¼ 0.05), and those with low RRM1 levels showed a tendency to better response in the gemcitabine/cisplatin arm. Time to progression was influenced by b-tubulin III (P ¼ 0.03) and stathmin (P ¼ 0.05) levels in the vinorelbine/cisplatin arm, and there was a tendency toward correlation between b-tubulin III levels and time to progression in the paclitaxel/carboplatin arm. RRM1 levels influenced time to progression (P ¼ 0.05) and even more so, survival (P ¼ 0.0028) in the gemcitabine/cisplatin arm. The predictive value of b-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival. Oncogene (2003 Oncogene ( ) 22, 3548-3553. doi:10.1038 Keywords: NSCLC; gene expression; b-tubulin III; RRM1; stathmin Metastatic lung cancer remains the most common fatal cancer in Western countries. Platinum-based chemotherapy combinations with new cytotoxic drugs like gemcitabine (Crino`et al., 1997) , vinorelbine (Wozniak et al., 1998) and paclitaxel (Bonomi et al., 2000) yield radiographic response in a meaningful number of patients but time to progression still hovers at 4 months from the start of chemotherapy. Several randomized trials have compared these three different chemotherapy combinations but results have been similar across the three regimens. A recent Italian multicenter randomized study of 612 non-small-cell lung cancer (NSCLC) patients treated with either gemcitabine/cisplatin, vinorelbine/cisplatin or paclitaxel/carboplatin showed no differences in time to progression among the three arms (Scagliotti et al., 2001) .
Several lines of preclinical research indicate that mRNA overexpression of selected genes can contribute to chemoresistance to gemcitabine, vinorelbine or paclitaxel, and it seems that pharmacogenomic assessment can help prolong time to progression through tailored chemotherapy.
Microtubules are dynamic polymers that play a role in cell division. Upon entry into mitosis, they disassemble and then reassemble into a highly dynamic mitotic spindle (Amayed et al., 2002) . Microtubuleinteracting agents like paclitaxel and vinorelbine inhibit spindle dynamics, thereby leading to a block in mitosis. One mechanism of resistance to these agents has been identified as b-tubulin class I (HM40) mutations, which were found in paclitaxel-and epothilone-resistant cell lines (Giannakakou et al., 1997 (Giannakakou et al., , 2000a He et al., 2001) . However, no HM40 mutations were identified in patient samples or nondrug-selected human cancer cell lines (Kelley et al., 2001; Sˇale et al., 2002; Tsurutani et al., 2002) . Previously, tubulin mutations had been described in NSCLC patients (Monzo et al., 1999) ; however, when the sequences were checked using BLAST, many of the substitutions were found to correspond to pseudogenes (Monzo et al., 2002) . Using quantitative PCR, the expression of HM40 was found to be the predominant b-tubulin isotype in human ovarian carcinoma xenografts, and increased expression of btubulin class III (Hb4) correlated with paclitaxel resistance in ovarian cancer cell lines (Nicoletti et al., 2001) . Altered expression of b-tubulin class III has also been associated with paclitaxel resistance in ovarian tumors, in human prostate carcinoma cells and in NSCLC cell lines (Kavallaris et al., 1997 (Kavallaris et al., , 1999 Ranganathan et al., 1998) .
Stathmin is a member of the SCG 10 family, which is enriched in the nerve growth cone and regulates microtubule dynamics, interacting with tubulin in a phosphorylation-dependent manner, sequestering free tubulin and hence promoting microtubule depolymerization in vitro (Brattsand, 2000) . Stathmin overexpression can enhance microtubule disassembly (Iwata et al., 2002) . Stathmin expression has been associated with lung cancer cell sensitivity to vindesine and may be a surrogate marker for vinca alkaloid chemosensitivity in lung cancer (Nishio et al., 2001) . In contrast, in paclitaxel-resistant leukemic cells, antisense inhibition of Stathmin leads to increased chemosensitivity (Iancu et al., 2000) .
Ribonucleotide reductase (RR) is the rate-limiting enzyme of the DNA synthesis pathway and converts ribonucleoside diphosphate to deoxyribonucleoside diphosphate, which is essential for DNA synthesis and repair. RR consists of two subunits, M1 and M2 . The M1 subunit controls substrate specificity and global on/off enzyme activity, while the M2 subunit carries the catalytic domain responsible for substrate conversion. RRM1 also acts as a putative tumor suppressor and has been identified within the centromeric part of chromosome segment 11p15.5 . This region, called LOH11A, is frequently lost in NSCLC; it has been completely mapped and sequenced (Zhao and Bepler, 2001) , and loss of heterozygosity in this region has been shown to be highly predictive of poor survival in resected NSCLC patients (Bepler et al., 2002) . RR overexpression was related to gemcitabine resistance in human oropharyngeal epidermoid carcinoma KB cells (Goan et al., 1999) .
Benzo[a]pyrene diol epoxide is an active metabolite of tobacco procarcinogen benzo[a]pyrene; it decreases retinoic acid receptor-b in esophageal cancer cells, upregulating AP-1 and inducing COX-2 expression (Song and Xu, 2001) . Interestingly, nonsteroidal antiinflammatory drugs decrease cell viability in COX-2-expressing esophageal cancer cell lines but not in COX-2-negative cell lines . Recent findings show that COX-2 overexpression in the skin of transgenic mice resulted in suppression of tumor development (Bol et al., 2002) . Besides causing microtubule bundling, paclitaxel activates AP-1 (Blagosklonny and Fojo, 1999).
Glutathione S-transferases (GSTs) are a family of cytosolic enzymes involved in the detoxification of various exogenous as well as endogenous reactive species. Increased tolerance to toxic xenobiotics and to cytotoxic drugs has been associated with increased GST expression (Goto et al., 1995) . A majority of drugresistant cell lines show an increase in GSTP1 levels (Harbottle, 2002) .
To elucidate the relation between b-tubulin III, stathmin, RRM1, COX-2 and GSTP1, and response to gemcitabine, vinorelbine and paclitaxel, we analysed mRNA expression of these genes in pretreatment tissue biopsies from 75 patients of the 612 included in the Scagliotti et al. (2001) trial. RNA isolation from paraffin-embedded specimens was carried out according to a proprietary procedure (US patent number 6,248,535). After RNA isolation, cDNA was prepared from each sample as described previously (Lord et al., 2000) . Relative cDNA quantitation for b-tubulin III, stathmin, RRM1, COX-2, GSTP1 and an internal reference gene (b-actin) was carried out using a fluorescence-based, real-time detection method (ABI PRISM 7700 Sequence Detection System; TaqMan; Applied Biosystems, Foster City, CA, USA), as described previously (Lord et al., 2000 (Lord et al., , 2002 Gibson et al., 1996; Heid et al., 1996) . The primers and probe sequences used are given below and in Table 1 . In each case, the first primer is the forward PCR primer, the second is the reverse PCR primer, and the third is the Table 1 Gene-specific primer sequences
Gene
Primer sequence 0 -AC-CACCACGGCCGAGCGG-3 0 TAMRA. The PCR reaction mixture consisted of 600 nm of each primer, 200 nm probe, 2.5 U of AmpliTaq Gold polymerase, 200 mm each dATP, dCTP, dGTP, 400 mm dUTP, 5.5 mm MgCl 2 , and 1 Â Taqman Buffer A containing a reference dye, to a final volume of 25 ml (all reagents were from Applied Biosystems, Foster City, CA, USA). Cycling conditions were 501C for 10 s, 951C for 10 min, followed by 46 cycles at 951C for 15 s and 601C for 1 min. Colon, liver and lung RNAs (all from Stratagene, La Jolla, CA, USA) were used as control calibrators on each plate. All gene expression analyses were performed in a blinded fashion with the laboratory investigators unaware of the clinical data.
The threshold cycle (C T ) was the fractional cycle number at which the fluorescence generated by cleavage of the probe exceeded a fixed level above baseline. The relative amount of tissue target mRNA standardized against the amount of b-actin mRNA was expressed as
The ratio of the number of target mRNA copies to the number of bactin mRNA copies was then calculated as 2 -DCT Â K, where K is a constant.
For statistical analysis of the quantitative differences in b-tubulin, stathmin, RRM1, COX-2 and GSTP1 mRNA levels, we used the maximal w 2 method to determine a cutoff value to segregate patients into groups with low or high transcript levels. To determine a P value, we used bootstrap-like simulations to estimate the distribution of a maximal w 2 statistic. Proportions were compared by use of Fisher's exact test. The Kaplan-Meier test for survival was used. The log-rank test was applied to compare survival rates between subgroups. Differences of Po0.05 were considered statistically significant. All analyses were performed with the SPSS software package, version 10.0.5 (SPSS Inc., Chicago, IL, USA).
Clinical characteristics and gene mRNA levels are shown in Table 2 . No significant differences in main clinical-pathologic characteristics, median transcript levels or response were observed between the 22 patients treated with gemcitabine/cisplatin, the 25 treated with vinorelbine/cisplatin, and the 28 treated with paclitaxel/ carboplatin. COX-2 levels were higher in adenocarcinoma (6.14) and large-cell undifferentiated carcinoma (11.37) than in squamous cell carcinoma (2.37) (P ¼ 0.04). When response in the vinorelbine/cisplatin arm was broken down by b-tubulin III expression (cutoff of 0.5), partial response (50% decrease in tumor size) was observed in 1/4 patients with low levels and in 5/13 with high levels. In the paclitaxel/carboplatin arm, partial response was observed in 5/9 patients with low levels and in 1/11 with high levels (P ¼ 0.05). When response to vinorelbine/cisplatin was broken down by stathmin expression (cutoff of 5), partial response was observed in 2/5 with low levels and in 1/8 with high levels. In the paclitaxel/carboplatin arm, partial response was observed in 3/14 with low levels and in 3/8 with high levels. When response to gemcitabine/cisplatin was broken down by RRM1 expression (cutoff of 1.4), partial response was observed in 6/12 with low levels and in 1/4 with high levels. There were no differences in response in any of the three arms when broken down by COX-2 or GSTP1 mRNA levels.
Overall time to progression and survival for these 75 patients, broken down by treatment arm, were similar to those for all 612 patients included in the original randomized trial (Scagliotti et al., 2001) . A cutoff of 1 was used to correlate b-tubulin III with time to progression in the vinorelbine/cisplatin and the paclitaxel/carboplatin arms. In the vinorelbine/cisplatin arm, median time to progression was 7.3 months for the 10 patients with low b-tubulin III expression and 4.1 months for the 12 patients with high expression (P ¼ 0.04) (Figure 1 ). In the paclitaxel/carboplatin arm, median time to progression was 6.8 months for the 15 patients with low b-tubulin III expression and 4.2 months for the seven patients with high expression. Using a cutoff of 5 for stathmin expression, in the vinorelbine/cisplatin arm, median time to progression was 6.4 months for the seven patients with low stathmin expression and 2.1 months for the 11 patients with high expression (P ¼ 0.05) (Figure 2 ). In the paclitaxel/ carboplatin arm, median time to progression was 6.8 months for the 14 patients with low stathmin levels and 5.5 months for the eight patients with high levels. In the gemcitabine/cisplatin arm (cutoff of 1.4), median time to progression was 7.6 months for the 13 patients with low RRM1 levels and 4.3 months for the five with high levels (P ¼ 0.05). No differences in time to progression were observed according to COX-2 or GSTP1 transcripts.
In the vinorelbine/cisplatin arm, median survival was 11 months for the 10 patients with low b-tubulin III levels and 8.1 months for the 12 patients with high levels. In the paclitaxel/carboplatin arm, median survival was 9.4 months for the 15 patients with low levels and 13.9 months for the seven patients with high levels. In the vinorelbine/cisplatin arm, median survival was 9.3 months for the seven patients with low stathmin levels and 11 months for the 11 patients with high levels. In the paclitaxel/carboplatin arm, median survival was 8.5 months for the 14 patients with low levels and 9.4 months for the eight patients with high levels. In the gemcitabine/cisplatin arm, median survival was 15.5 months for the eight patients with low RRM1 levels and 6.8 months for the eight patients with high levels (P ¼ 0.0028) (Figure 3 ). In the paclitaxel/carboplatin arm, median survival was 8.5 months for 12 patients with low COX-2 levels and 13.9 months for those with high levels (P ¼ 0.006). No differences in survival were observed according to COX-2 levels in the other two arms, and no differences were observed in any of the three arms according to GSTP1 levels.
Great progress has been made in recent years in the study of genetic abnormalities involved in NSCLC. If we intend to use this progress to develop more effective therapeutic strategies for NSCLC management, we need to identify specific targets that determine chemosensitivity to available cytotoxic regimens. This study provides data that upregulation of specific transcripts Stathmin mRNA levels influenced time to progression in the vinorelbine/cisplatin arm (P ¼ 0.05). In the gemcitabine/cisplatin arm, RRM1 mRNA levels had a highly significant effect on survival (P ¼ 0.0028) as well as an effect on time to progression (P ¼ 0.05). Admittedly, the conclusions that can be drawn from this study are limited by the small number of tumor samples available for examination and by the retrospective nature of the study. Also, a significant number of patients received second-line or salvage chemotherapy at the time of relapse, which limits the value of patient survival as a measure of the efficacy of first-line therapy (Ramsey et al., 2002) . Patients in the gemcitabine/cisplatin arm received vinorelbine-or taxane-based therapy, and those in the vinorelbine/cisplatin and paclitaxel/carboplatin arms received gemcitabine-based therapy (Scagliotti et al., 2001) . Thus, the use of salvage regimens in this study may have diminished the true magnitude of the investigated gene/chemotherapy interactions.
Both the vinorelbine/cisplatin (Le Chevalier et al., 1994) and the gemcitabine/cisplatin (Cardenal et al., 1999; Crino`et al., 1999; Sandler et al., 2000) combinations are widely used in many countries, and the predictive value of b-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials. By eliminating the drawbacks inherent in a small retrospective study, the results of these trials will help oncologists to tailor chemotherapy to improve patient survival.
